Surrozen, Inc.
$32.25
▼
-2%
2026-04-21 09:36:01
www.surrozen.com
NCM: SRZN
Explore Surrozen, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$362.52 M
Current Price
$32.25
52W High / Low
$33.22 / $5.9
Stock P/E
—
Book Value
$-19.21
Dividend Yield
—
ROCE
-47.4%
ROE
231.45%
Face Value
—
EPS
$-32.37
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
44
Beta
0.52
Debt / Equity
-0.04
Current Ratio
9.22
Quick Ratio
9.22
Forward P/E
-7.91
Price / Sales
95.4
Enterprise Value
$241.32 M
EV / EBITDA
-5.81
EV / Revenue
69.4
Rating
None
Target Price
$38.75
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BioCardia, Inc. | $1.25 | — | $12.91 M | — | -843.83% | -9.5% | $3.2 / $1 | $0.08 |
| 2. | Daré Bioscience, Inc. | $2.87 | — | $41.79 M | — | -154.2% | 845.53% | $9.19 / $1.27 | $0.2 |
| 3. | Ginkgo Bioworks Holdings, Inc. | $7.98 | — | $492.71 M | — | -29.68% | -51.08% | $17.58 / $5.37 | $8.74 |
| 4. | Ardelyx, Inc. | $6.3 | — | $1.59 B | — | -9.92% | -36.21% | $8.4 / $3.21 | $0.68 |
| 5. | Matinas BioPharma Holdings, Inc. | $0.55 | — | $3.52 M | — | -202.13% | -1.67% | $3.09 / $0.48 | $1.09 |
| 6. | Verrica Pharmaceuticals Inc. | $6.38 | — | $109.6 M | — | -38.9% | -2.4% | $9.82 / $3.28 | $1.44 |
| 7. | C4 Therapeutics, Inc. | $2.99 | — | $284.93 M | — | -32.05% | -44.44% | $3.82 / $1.09 | $2.65 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.53 M | 0.98 M | 0.98 M | 0.98 M | 0.66 M | — |
| Operating Profit | -12.64 M | -10.88 M | -9.02 M | -9.55 M | -8.59 M | — |
| Net Profit | -183.16 M | -71.64 M | 39.75 M | -26.97 M | -28.04 M | — |
| EPS in Rs | -15.57 | -6.09 | 3.38 | -2.29 | -2.38 | -0.44 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 3.48 M | 10.65 M | 0 M | 12.5 M |
| Operating Profit | -42.09 M | -25.54 M | -43.03 M | -44.34 M |
| Net Profit | -242.03 M | -63.56 M | -43.04 M | -36 M |
| EPS in Rs | -20.58 | -5.4 | -3.66 | -3.06 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 98.73 M | 48.47 M | 46.08 M | 89.44 M |
| Total Liabilities | 286.49 M | 69.85 M | 8.14 M | 13.43 M |
| Equity | -187.76 M | -21.38 M | 37.94 M | 76 M |
| Current Assets | 91.56 M | 38.93 M | 41.13 M | 81.31 M |
| Current Liabilities | 9.93 M | 7.32 M | 7.15 M | 9.73 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -30.24 M | -17.63 M | -40.36 M | -44.15 M |
| Investing CF | -0.13 M | -0.03 M | 51.72 M | 38.31 M |
| Financing CF | 85.05 M | 16.18 M | 0.28 M | -2.56 M |
| Free CF | -30.37 M | -17.65 M | -40.76 M | -44.87 M |
| Capex | -0.13 M | -0.03 M | -0.4 M | -0.73 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -67.37% | — | -100% | — |
| Earnings Growth % | -280.76% | -47.68% | -19.55% | — |
| Profit Margin % | -6960.77% | -596.56% | — | -288.03% |
| Operating Margin % | -1210.58% | -239.69% | — | -354.71% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1195.14% | -226.16% | — | -339.07% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-12-14 | 1:0.0666667 |